CLN-0046: Treatment of AMD Subjects With OTX-TKI

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

OTX-TKI

OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

DRUG

OTX-TKI

OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

DRUG

OTX-TKI

OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

DRUG

OTX-TKI

OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

DRUG

Anti-VEGF

Standard of care therapy used to block vascular endothelial growth factor

DRUG

OTX-TKI

OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

DRUG

Anti-VEGF

Standard of care therapy used to block vascular endothelial growth factor

Trial Locations (6)

Unknown

Ocular Therapeutix, Inc., Sydney

Ocular Therapeutiux, Inc., Sydney

Ocular Therapeutiux, Inc., Sydney

Ocular Therapeutix, Inc., Adelaide

Ocular Therapeutix, Inc., Albury

Ocular Therapeutix, Inc., Melbourne

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT03630315 - CLN-0046: Treatment of AMD Subjects With OTX-TKI | Biotech Hunter | Biotech Hunter